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Abstract: 
Latent TB infections are a result of the disease’s ability to evade host immune defenses and remain in a 
quiescent asymptomatic state. Clonal expansion of T-cells within granulomas of individuals with active and latent 
TB provides an opportunity to determine the antigens capable of promoting an adaptive immune response within a 
human subject. Using sequence information from T-cells of patients with Latent Tuberculosis, T cell receptor (TCR) 
variable region inserts were designed. The objective of this work is to utilize Golden Gate cloning of the compiled 
TCR sequences to create a repertoire of specific TCRs for eventual expression using retroviral vectors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
 
Epidemiology: 
Mycobacterium tuberculosis is the infectious organism responsible for causing the majority of Tuberculosis 
(TB) disease outbreaks and infections (34). The World Health Organization reported in 2018 that TB was 
responsible for 1.3 million deaths in HIV-negative, and 300,000 in HIV-positive individuals, and that 10.0 million 
people developed the disease globally (45). Active or symptomatic TB is transmitted as an aerosol through the 
respiratory tract and targets alveolar macrophages as the site of primary infection (11). Early clearance of M. 
tuberculosis infection is attributed to the innate immune response and alveolar macrophage elimination of the 
infection without initiation of the adaptive immune system (42, 26). Due to M. tuberculosis’ close evolution with the 
human host immune system, disease progression increases when components of the adaptive immune response are 
recruited. Analysis of Mycobacterium tuberculosis Complex (MTBC) phylogeography suggests that MTBC has 
been undergoing co-evolution with humans for tens of thousands of years (7). This co-evolutionary relationship is 
demonstrated predominantly during persistence of latent TB infections (LTBI) in the diseases’ ability to evade host 
immune defenses and remain in a quiescent asymptomatic state (3). It is hypothesized that this alternative disease 
progression allowed the human-obligate pathogen to remain dormant until the individual passes reproductive age 
and then progress to the clinically active disease in older age. This mechanism would have allowed ancient 
Mycobacterium tuberculosis to retain its human host pool while avoiding self-extinction in small groups of hunter 
gatherers (10, 34).  
 
Immunology: 
 Current research investigations into TB are directed toward pursuing the means to treat or promote the 
immune system’s defense and clearance of LTBI. Targeting LTBI would reduce the reservoir of potentially 
infectious TB within the population and reduce overall transmission and disease prevalence (13). The asymptomatic 
stage of infection is mediated via the M. tuberculosis: macrophage interaction (39). Initiated by alveolar macrophage 
phagocytosis of M. tuberculosis and promoted by either mannose or surfactant protein A (38, 16, 39) the bacteria is 
sequestered to an intracellular vacuole where virulence factors such as lipoarabinomannan (LAM) inhibit 
phagosomal maturation and elimination of the pathogen (43, 22). Persistence of the Mycobacterium tuberculosis 
(Mtb) is achieved through the development of granulomas that function to contain and localize the adaptive immune 
response. These accumulations of infected alveolar macrophages, interstitial macrophages, lung myeloid dendritic 
cells, monocytes, and neutrophils create a balance of pro/anti-inflammatory responses surrounding a necrotic center 
(17, 18). Utilizing genes that inhibit apoptosis of the infected cells M. tuberculosis maintains a favorable replicative 
environment until determinants cause necrosis of the infected host cell and release of internally replicated bacterium 
(4, 19). Stimulated apoptosis of the infected macrophages and dendritic cells are promoted via Mtb translocation 
from the phagosome into the cytosol (4, 41). T-cell mediated immunity is dually manipulated by Mtb targeting 
antigen presentation on both MHC class I and II. CD4 T-cells are unable to identify Mtb infected antigen presenting 
cells within the lung as a result of the 19-kDa lipoprotein antigen (LpqH) which reduces cellular presentation of 
MHC II in infected macrophages (4, 32, 14). Cytotoxic CD8 T-cell response mediated by the MHC I complex, an 
important pathway for immunity against intracellular pathogens, provides one potential pathway to identify effective 
adaptive immune system response toward infected antigen presenting cells (APCs) (4). This pathway is reliant upon 
Mtb antigen presentation on MHC I during translocation into the cytosol or via cross-presentation from the 
phagosome to the recycled MHC I from the ER (36, 4, 21, 19). An additional process for presenting Mtb antigens on 
MHC I is possible as uninfected APCs can uptake cellular debris from infected cells that have undergone apoptosis 
(4, 37). 
 
T-Cell Mediated Immunity: 
 Naive CD8 T-cell priming post recognition of pathogen-activated MHC class I APCs propagates clonal 
expansion and differentiation of effector T-cells (29, 33). Differentiated effector T-cells, specifically cytotoxic T-
cells, are capable of identifying infected APCs presenting Mtb antigens on MHC I receptors and facilitating lysis or 
apoptosis of these infected cells (44). 
Clonal expansion of T-cells within granulomas of individuals with LTBI provides an opportunity to 
determine Mtb antigens capable of promoting an adaptive immune response within a human subject (33). 
Sequencing of these granulomas reveals the frequencies of clonally expanded T-cell receptors (TCRs) that are 
potentially specific to Mtb antigens. Through collaboration with a South African research center, human granulomas 
from patients with Tb were sequenced and frequencies of TCR alpha and beta variable chains and hypervariable 
regions were compiled. The objective of this study is to utilize Golden Gate cloning of the compiled TCR sequences 
to create a repertoire of specific TCRs for expression in Jurkat cells using retroviral vectors and analysis via flow 
cytometry of the antigens the TCRs are responding to. 
 
T-Cell Receptor Complex: 
T-Cell Receptors (TCRs) are transmembrane heterodimers composed of complementary determining 
regions (CDRs) present on T-lymphocytes of the adaptive immune system (5, 29). The two amino acid chains of 
interest, dimerized via a disulfide bond are the Alpha and Beta chains (5, 29). Alternatively, these chains can be 
composed of Gamma and Delta sequences (30). Studies have demonstrated Gamma: Delta TCR complexes operate 
via dissimilar mechanisms of antigen presentation, recognition, and signaling in comparison to Alpha: Beta 
complexes (25, 1). Due to limited research in elucidating these dissimilar mechanisms, Gamma: Delta TCRs are not 
considered in this study (12). The analysis of identifying Human TCRs responding to Mtb antigens in this research 
is focused specifically to Alpha: Beta complex TCRs. The fundamental structure of TCR Alpha: Beta complexes is 
illustrated in Image 1.  
 
Image 1, Basic α:β TCR Complex structure, illustrates junction diversity and localization of CDR3 
hypervariable region 
  
Both Alpha and Beta chains can be further divided into variable (Vα/V β) and constant regions (Cα/Cβ) 
(29). Regions of the variable alpha (Vα) chain are composed of the Vα and Jα subunits (31). Variable beta (Vβ) 
chains are comprised of the Vβ, Dβ, and Jβ subunits (40, 5, 44). Subunits are classified as variable (V), diversity 
(D), and Joining (J) (5, 44). These classifications correspond to components of the TCR “hypervariable region” 
(CDR3) (8, 1, 10). The Vα/Vβ regions are further divided into three complementary determining regions (CDRs) 
classified as CDR1, CDR2, and CDR3 (6, 15, 40, 31). TCR functionality via the MHC: peptide: TCR ternary 
complex relies on these CDR sites in which each alpha and beta chain forms three loops (2, 44, 20, 15). CDR1 and 
CDR2 relate to the “germline” variable gene segments and form the peripheral loops of the TCR that engage with 
the MHC complex, mediating both MHC recognition and specificity (28, 2). The CDR3 selectively contacts the 
specific complementary peptide fragment presented on the MHC complex binding groove (40, 2, 6). Through these 
complementary determining regions, MHC recognition and specificity is created by CDR1 and CDR2 while CDR3 
conveys specificity to the bound peptide fragment (40, 2, 6, 31). The diversity of CDR3 regions, which allows the T-
cell to recognize the variety of intracellularly digested peptide fragments, is due to junctional sequence diversity (40, 
20). During gene rearrangement of the V, D, and J TCR regions, both the alpha and beta chain modifications are 
implemented in the form of both N- and P- nucleotides (20, 40). N- nucleotides are inserted between the junctions of 
the V, D, and J segments during gene segment arrangement (20). Similarly P- nucleotides are found at these gene 
segment junction and are reciprocal repeats of the sequences located at the terminal ends of the gene segments (20). 
  
Golden Gate Reaction Scheme: 
 Golden Gate Cloning is an effective method for taking advantage of the modular nature of TCR genes and 
preparing them in constructs for retroviral expression (8). This cloning strategy utilizes the Type IIS restriction 
enzyme to implement restriction cut sites upstream of Type IIS recognition sites (8, 9, 35). Cut sites located 
downstream of recognition sequence and residual overhangs, respectively promote removal of restriction enzyme 
responsiveness to final expression constructs and directionality during ligation resulting in a highly efficient single 
step reaction (8). Removal of recognition sequences from the final ligated construct allows overhangs to be specified 
to the intended sequence without residual scarring of the sequence of interest as seen in alternative restriction 
enzyme practices. Image 2 illustrates the design of the acceptor vector and shows the directionality of the BbsI cut 
sites and residual overhangs.  
 
 
Image 2, Golden Gate MSGV Acceptor Vector, reveals the location of the TCR constant regions in addition to 
presence of P2A self-cleavage site 
 
Vector design was based off of previous work from David Ott’s lab, MSGV Hu-Acceptor and MSGV Hu-
Acceptor PGK-NFGR plasmids available through Addgene (8, 9, Addgene plasmid # 64270 & 64269). These 
predesigned Acceptor Plasmids are unique in that they include MSGV retroviral components, both TCR constant 
alpha and beta regions joined by a P2A multicistronic self-cleavage site, and BbsI Type IIS restriction enzyme 
recognition sites to facilitate insertion of TCR alpha and beta variable regions (8, 9, Addgene). The P2A (porcine 
teschovirus-1 2A) has been noted to possess the highest “self-cleavage” efficiency of the 2A peptides, resulting in 
co-expression of adjacent genes (27, 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methodology: 
 
Designing TCR Variable Inserts:  
 TCR alpha and beta chain variable regions were designed by combining the sequenced V, D, and J gene 
segments from the human subjects and identifying the junctional N- and P- nucleotides to create the specific amino 
acid sequence of the CDR3. Each subject’s TCR alleles were determined via sequencing. The Vα and Vβ chains are 
comprised of the TRAV, TRAJ, TRBV, TRBD, and TRBJ alleles (24). Provided with the amino acid sequence of 
the TCR specific CDR3, these allele sequences were combined using ApE and SnapGene software while the allele 
sequences were obtained from the online IMGT database. Using the Expansy software to translate the DNA 
sequence to the amino acid sequence, the junctional insertions sites of the N- and P- nucleotides were determined. 
Alpha and Beta chain variable sequences were then flanked by BbsI type IIs restriction enzyme sites. Presence of 
these sites would then allow these variable inserts to be used in Golden Gate reaction. The reading frame of the 
variable insert was confirmed within the Acceptor Vectors from David Ott using the NEB Golden Gate software. 
The variable acceptor constructs were designed in the pUC57 plasmid with ampicillin resistance and created by 
Addgene.     
 
Plasmid Transformation: 
TCR variable chain entry pUC57 plasmids from Addgene were transformed into NEB 5-alpha competent 
E. coli HF (New England Biolabs) and cultured in SOC outgrowth media. These transformants were then grown on 
100ug/mL Amp LB agar plate and colonies were selected for plasmid preparation. The Qiagen: Miniprep (Qiagen) 
kit was used for both Entry plasmids and Acceptor plasmids. Products of the miniprep kit were analyzed via 
Nanodrop for purity and DNA concentration.  
 
Confirming Acceptor and Entry Plasmid Sequences: 
The Acceptor Plasmid MSGV Hu-Acceptor and MSGV Hu-Acceptor PGK-NGFR (8, Addgene plasmid # 
64270 & 64269) were digested using 1uL of BsrGI (New England Biolabs), for 30 min, at 37C to confirm intended 
plasmid size through restriction digest and gel electrophoresis on a 0.5% gel for 60 min at 100V loading 15 uL of 
product and 2 uL of loading dye. Each gel completed all utilized the 1Kb Plus DNA Ladder (Invitrogen). The 
identified bands from the digest revealed the anticipated results of Hu-Acceptor 667, 6072 and Hu-NGFR 665, 1735, 
5669 (Fig 7). 
In order to confirm sequences of the BbsI recognition sites and overhangs in the Acceptor plasmids the 
following primers were designed by imputing the Acceptor plasmid sequences into Benchling, and ordered through 
IDT (Integrated DNA Technologies). Primers were designed with complementarity to portions of the Acceptor 
Plasmid sequence. The primers for the Vα entry sequence site are upstream of the Vα site and inward while the 
downstream primer anneals in the upstream portion of the Cα region for the reverse sequence of the Vα insert. 
Primer designations for the Vβ region follow a similar design where the upstream primer is specific to the terminal 
Cβ sequence and the downstream primers is complementary to the start of the Cβ region. Using this format for 
primer specificity these primers can be used across Vα/Vβ insert variations allowing a more streamlined procedure 
for completing sequencing of the TCR regions of interest. Figure 1 presents the designed primers. 
 
Vα-Forward (Tm = 58.2°C) 
5’ CACGAAGTCTGGAGACCTCTGG 3’ 
 
Cα-Reverse (Tm = 58.5°C) 
5’ CTTTTCCACCAGCTTCACGTCG 3’ 
 
Cα/Vβ-Forward (Tm = 57.7°C) 
5’ CGAGGACACATTCTTCCCAAGC 3’ 
   
Cβ-Reverse (Tm = 57.9°C) 
5’ TCTTTCAGAGGCTGGGGATCG 3’ 
Figure 1, Primers Designed for specificity with the Golden Gate Acceptor Plasmids 
 
Eton Bioscience Inc. provided sequencing services to provide sequence data used to confirm the correct 
Acceptor sequence. Restriction digest using the EcoRI and HindIII restriction enzyme (New England Biolabs) was 
used to confirm the correct anticipated size of the pUC57 plasmid containing the TCR variable insert. 0.5 uL of both 
EcoRI and HindIII, using 1 ug of DNA were digested at 37C for 2 hours and inactivated at 80C for 10 min. 
Digestion products were run on a 1% EtBr gel at 110V for 60 min. The pUC57 digest with EcoRI and HindIII 
produced the anticipated bands Vα insert 497, 2635 and Vβ insert 515, 2635 (Fig 8). 
 
PCR Preparation of Variable Inserts: 
 Primers specific for the pUC57 plasmid variable alpha and beta inserts were designed and used to perform 
PCR amplification of the variable insert for use in the Golden Gate Reaction (Figure 2).  The primers were designed 
to recognize outside of variable insert of the entry plasmid allowing the primers to be used across the pUC57 entry 
vectors.   
     pUC57 Forward (Tm = 57.5°C) 
     5’ CAGTGAATTCGAGCTCGGTACC 3’ 
  
     puC57 Reverse (Tm = 58.2°C) 
     5’ TGTTGTGTGGAATTGTGAGCGG 3’ 
Figure 2, Primers Designed for specificity with the pUC57 Plasmid 
 
PCR was conducted using 10X Taq Buffer and Taq polymerase (Invitrogen #18067017), 1 uL of primer, 
and 2 uL of pUC57 entry vector template. Thermocycler conditions were run at 94°C/5 min, followed by 30 cycles 
of 94°C/30 s, 54°C/15 s, 68°C/45 s, and then 68°C/5 min, and a 4°C hold. 4 uL of PCR products was subsequently 
run on a 1% EtBr gel at 110V for 60 min (Fig 9,10). The expected amplicons of Vα and Vβ at 572 bp and 590 bp 
respectively were purified from the gel using Qiagen PCR Cleanup Kit (Qiagen) and concentration and purity 
determined by Nanodrop. These purified amplicons were used as the variable inserts in the Golden Gate Reaction 
scheme. 
 
Golden Gate Reaction: 
 The Golden Gate reaction was completed using 50 ng of both variable entry plasmids in addition to 100 ng 
of acceptor sequence. Per 50 ng Entry and 100 ng Acceptor DNA, 2 uL of T4 DNA ligase buffer, 2 uL BbsI, and 
1uL T4 ligase were added. Restriction and ligation was completed in the same reaction as both BbsI-HF and T4 
ligase (New England Biolabs) were added and run in the thermocycler programs presented (Figure 3 & 4). 
 
 
 
Figure 3, First Thermocycler Program for Golden Gate Reaction 
 
After the initial restriction ligation was completed, 1uL of both ATP buffer and Plasmid safe exonuclease 
(Epicenter) was added to digest linear DNA fragments, followed by the thermocycler program in table 2. 
 
 
 
Figure 4, Second Thermocycler Program for Golden Gate Reaction 
 
The design of both reagent volumes and thermocycler settings are based off of the protocol followed by 
David Ott (8, 9). Confirmation of the Golden Gate constructs were completed through transformation of the Golden 
Gate Plasmids into NEB 5-alpha competent E. coli HF (New England Biolabs). Transformation was completed by 
adding 50 uL of thawed DH5 alpha competent E. coli and incubated on ice for 30 min prior to being heat shocked in 
a 42C water bath for exactly 30 seconds. Heat shock was followed by placing the tube of transformants on ice for 5 
min before adding 905 mL of SOC outgrowth media and incubated for 1 hr at 37C on shaker at 225 rpm. The 
transformants were plated on LB ampicillin (100mg/mL) plates. Digestion via BsrGI (New England Biolabs) was 
completed using the same procedure as the empty acceptor plasmids. The primers initially designed for confirming 
the Acceptor plasmid sequence also served as the primers to confirm appropriate variable insert positioning in the 
final Golden Gate constructs by sequencing services through Eton Bioscience Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: 
 
Initial Golden Gate Reaction: 
 The original design of the Golden Gate reaction scheme intended to use both the Acceptor and Entry 
plasmids in the one step reaction. Variable regions used in this initial reaction design were Vα-2.88 and Vβ-3.31. 
Both Acceptor Plasmid MSGV Hu-Acceptor and MSGV Hu-Acceptor PGK-NGFR (8, 9, Addgene plasmid # 64270 
& 64269) were used, these constructs were designated as Hu.1A & NGFR.1A. Concentrations and thermocycler 
protocol previously completed by David Ott’s lab was attempted and the Golden Gate constructs were transformed 
into DH5 alpha competent E. coli (New England Biolabs). Construct plasmids were isolated using the Qiagen: 
Miniprep Kit (Qiagen). To confirm presence and expected plasmid size these constructs were digested using the 
BsrGI restriction enzyme (New England Biolabs). These digest products are presented in Figure 5 & 6. 
 
 
Figure 5, Hu.1A (1-7) Golden Gate BsrGI Digest, 1% Agarose gel for 60 min at 100V 
 
 
Figure 6, NGFR.1A (1-7) Golden Gate BsrGI Digest, 1% Agarose gel for 60 min at 100V, variable insert plasmids 
pUC57 Vα and Vβ are both digests of EcoRI and HindIII. 
  
The digest present in Figures 5 & 6 was expected to produce bands corresponding to: Hu.1A (1-7) 1033, 
6420 and NGFR.1A (1-7) 1033, 1949, 5842. Instead digested Golden Gate constructs produced bands similar to 
undigested plasmid constructs. Noted in Figure 5 the pUC57 Vα insert fragment aligns with digests of the Golden 
Gate Constructs. From these results it was proposed that during the Golden Gate reaction scheme, undigested 
pUC57 entry plasmids remained in the mixture and were subsequently not removed during the cleanup utilizing the 
plasmid safe exonuclease. This would have allowed the pUC57 entry plasmids to be transformed into the DH5 alpha 
E. coli (New England Biolabs) due to the pUC57 plasmid sharing the ampicillin resistance as the Golden Gate 
Acceptor plasmid.  
 
Troubleshooting the Reaction Design: 
To establish that both the entry and acceptor plasmids had not been altered due to transformation, 
restriction digests were completed of each to identify the expected band size. The Acceptor Plasmids MSGV Hu-
Acceptor and MSGV Hu-Acceptor PGK-NGFR (8, 9, Addgene plasmid # 64270 & 64269) were digested using the 
BsrGI restriction enzyme (New England Biolabs) and the gel digest is presented in Figure 7.  
 
 
Figure 7, Hu and NGFR Acceptor BsrGI Digest, run on 0.5% gel for 60 min at 100V 
 
The identified bands from the digest (Fig. 7) revealed the anticipated results of Hu-Acceptor 667, 6072 and 
Hu-NGFR 665, 1735, 5669. This digest provided evidence to support that the plasmid is the expected size. In order 
to confirm the sequences of the BbsI type IIS restriction sites and the specific directional overhangs the primers 
designed for sequencing of the Golden Gate constructs (Fig. 1) to confirm variable insert reading frame was used for 
the empty Acceptor. The sequence alignments completed from the sequence data provided from Eton Bioscience 
confirmed the correct and anticipated BbsI restriction sites and overhangs.  
 Confirmation of the Entry pUC57 size was completed using the EcoRI and HindIII restriction enzyme 
(New England Biolabs). The results of the digest are present in Figure 8.  
 
Figure 8, pUC57 Entry plasmid EcoRI and HindIII digest, using Vα-2.88 and Vβ-3.31, run on 1% gel at 110V for 60 
min 
 
The pUC57 digest with EcoRI and HindIII produced the anticipated bands Vα-2.88 insert 497, 2635 and 
Vβ-3.31 insert 515, 2635 (Fig 8). Plasmid size and sequence confirmation indicated that difficulties in producing the 
expected Golden Gate constructs was likely due to the presence of the ampicillin resistant pUC57 plasmid in the 
reaction scheme and subsequent transformation. 
PCR Production of Variable Inserts: 
 Removal of the pUC57 plasmid from the Golden Gate reaction was achieved by using PCR to amplify the 
Vα and Vβ inserts of the entry plasmids. Using these PCR products instead of the entry plasmids in the Golden Gate 
reaction allowed the subsequent transformation to be uncontaminated with additional plasmids containing ampicillin 
resistance. Using the primers specific to the pUC57 (Fig. 2) allowed the multiple variants of variable entry sites to 
be amplified and prepared. Figure 9 & 10 provide images of the gels that correspond to the PCR reaction products.  
 
Figure 9, PCR amplification of the Va-2.88 and Va-3.94 variable regions, run on 1% gel at 110V for 60 
min 
 
 
Figure 10, PCR amplification of Vβ-3.31 and Vβ-2.76 variable regions, run on 1% gel at 110V for 60 min 
 
The PCR amplicons for the 1A TCR construct had anticipated bands of: Vα-2.88, 572 and Vβ-3.31, 596 
represented on the gel (Fig 9 & 10). The variable inserts in addition to the inserts for the 2C TCR construct were 
isolated using the Qiagen PCR Cleanup Kit (Qiagen). Re-attempting the Golden Gate Reaction involved using the 
isolated PCR amplicons instead of the entry pUC57 plasmid. These PCR products still possessed the BbsI enzyme 
recognition sites in addition to the variable inserts since the primers designed for the PCR reaction annealed outside 
of the these regions of interest.  
 
Golden Gate Construct Digestion: 
 After troubleshooting the Golden Gate Reaction scheme and replacing the entry plasmids with the PCR 
products the same reaction procedure as previously attempted was implemented (Fig 3 & 4). The Golden Gate 
reaction was followed by transformation into DH5 alpha Competent E. coli (New England Biolabs) and the plasmids 
were isolated using the Qiagen Plasmid Miniprep Kit.   
Digestion of the Golden Gate Constructs using the BsrGI restriction enzyme (New England Biolabs) 
produced bands that indicate the presence of the Vα and Vβ variable inserts present within the Acceptor plasmid. 
The Golden Gate constructs are of the variable insert pairs 1A: Vα-2.88/ Vβ-331 and 2C: Vα-3.94 /Vβ-2.76. Both 
construct designs were digested in triplicate (1A.1-3 and 2C.1-3). The expected band sizes for Hu1A are 1033, 6420 
and Hu2C is 525, 6420. The expected band sizes for NGFR1A are 1033, 1949, 5842 and NGFR2C is 538, 1949, 
5842.   
 
Figure 11, Hu Golden Gate Digest with BsrGI, run on 1% gel at 110V for 60 min,   
 
The bands in Fig 11 corresponding to Hu.1A are present at the expected bp throughout Hu.1A 1-3. Hu.2C 
only has the expected bands for the construct of Hu.2C.2. Hu.2C.1 and Hu.2C.3 do not have bands at the anticipated 
525 length. 
 
Figure 12, NGFR Golden Gate Digest with BsrGI, run on 1% gel at 110V for 60 min.  
 
 The bands in Fig 12 corresponding to NGFR2C 1-3 all have approximate correspondence to what was 
anticipated for the digestion. The 1A construct with did not produce the bands at the anticipated length.  
Discussion: 
 
Interpreting Golden Gate Plasmid Digestion with BsrGI: 
 The digestion products based on band length presented in Figure 11 and 12 suggest that the Golden Gate 
reaction was successful in inserting the variable Vα and Vβ fragments specifically in the Hu acceptor in constructs 
Hu1A.1 – Hu1A.3 (Fig 11) and NGFR construct in NGFR2C.1 – NGFR2C.3 (Fig 12). Throughout these Acceptor 
vectors, and unlike the previous digest of Golden Gate constructs (Fig. 5 & 6) additional unexplainable bands that 
previously been present are not identified. Sequencing of these Golden Gate constructs using the designed primers 
(Fig 1) could potentially provide further insight into determining if the constructs reveal the presence of the variable 
inserts. This would help identify if these constructs were simply ill represented on the gel digestion. Otherwise, 
unpredicted sequence data could suggest problems in the specific overhangs causing interruptions in the variable 
insert.   
 
Correcting the Golden Gate Reaction Scheme: 
 The Golden Gate reaction was able to produce bands of the anticipated size in certain constructs when the 
pUC57 plasmid with ampicillin resistance was excluded from the reaction and subsequent procedures. Initially, the 
motivation for being able to use the entry plasmid instead of relying on PCR amplification was that the plasmids 
could easily be transformed and cultured to increase the amount of plasmid DNA containing variable inserts 
available for Golden Gate reactions. Avoiding the requirement for PCR was also pursued to reduce the cost of the 
Golden Gate scheme and remove the potential for changes in the sequence during amplification. The presence of the 
ampicillin resistance in the pUC57 suggests that due to the entry vector having a smaller size than the Golden Gate 
constructs the DH5 alpha competent E. coli were preferentially transformed by the smaller pUC57 plasmid as 
opposed to the larger Golden Gate plasmids. Replacing the pUC57 entry plasmid with a plasmid that contains an 
alternative antibiotic is predicted to alleviate the problems experienced in this Golden Gate scheme. Changing the 
antibiotic resistance in the entry plasmid is also predicted to allow the experimenter to use the Golden Gate scheme 
using the Acceptor and Entry plasmids and avoid PCR. Changing the antibiotic resistance in the entry plasmid 
would allow only the Acceptor plasmid to be specifically selected for in the growth on LB ampicillin following the 
Golden Gate reaction and transformation into NEB DH5 alpha competent E. coli (New England Biolabs). Colonies 
would not be afforded the potential to preferentially transform the smaller entry plasmid.   
 
Next Steps and Future Direction: 
 After sequencing the Golden Gate constructs using the primers in Figure 1 the next steps involve 
transduction of the Golden Gate plasmid into a murine retroviral packaging cell line. The murine retrovirus 
produced will subsequently be used to transfect the TCR construct into a Jurkat cell line. Using flow cytometry, the 
Jurkat cells will be analyzed to identify the presence of the transmembrane TCR complex. The murine NGFR will 
serve as a control to track the effectiveness of the transfection/transduction process through identification of its 
presence in the steps of analysis via flow cytometry. Using the modular design of the Golden Gate reaction scheme 
allows future researchers to create a repertoire of TCRs by interchanging Vα and Vβ sequences among TCR 
constructs. This functionality allows a variety of potential TCR constructs to be identified with a specific patient and 
investigated in terms of their capacity to recognize and respond to Mtb antigens.  
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